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We report on an HIV-negative but immunocompromised 
patient with disseminated acanthamoebiasis, granuloma-
tous, amoebic encephalitis, and underlying miliary tuber-
culosis and tuberculous meningitis. The patient responded 
favorably to treatment with miltefosine, an alkylphospho-
choline. The patient remained well with no signs of infection 
2 years after treatment cessation.
A 
25-year-old man from India, who had been living in 
Austria for 7 years and had no previous history of ma-
jor illnesses, was brought by ambulance to the hospital for 
dyspnea, cough, fever, and weight loss. During neurologic 
examination, a hearing impairment was suspected. The 
patient was unable to walk because of severe ataxia. Skin 
examination showed several necrotic ulcers with purulent 
discharge and black eschars, measuring 0.5 cm to 3 cm, 
located on the skull, back, neck, and arms (Figure 1, pan-
els A and B). Miliary tuberculosis (TB) of the lungs, liver, 
spleen, and kidneys was suspected on the basis of chest ra-
diography and computed tomography (CT) of chest and ab-
domen. Ziehl-Nielsen (ZN) staining for acid-fast bacilli in 
sputum, bronchial secretions, and lavage obtained through 
bronchoscopy was negative. PCR for Mycobacterium tu-
berculosis in bronchial secretions and serum was positive. 
Culture on Loewenstein agar resulted in growth of nonre-
sistant M. tuberculosis after 31 days. Blood cultures were 
negative for aerobic/anaerobic bacteria, mycobacteria, and 
fungi. Results of serologic tests were negative for Asper-
gillus, Candida, Cryptococcus, Histoplasma, Blastomyces, 
and Coccidioides spp. Severe immunosuppression with a 
CD4+ lymphocyte count of 182 cells/μL made HIV infec-
tion probable, but HIV testing results were negative. Crani-
al CT showed multiple small enhancing lesions in cerebral 
cortex and underlying white matter, pons, midbrain, and 
around most of the cisterns. On magnetic resonance imag-
ing (MRI), the lesions appeared as high T2 signal areas that 
enhanced heterogeneously or in a ringlike manner. These 
ﬁ  ndings were compatible with the diagnosis of meningoen-
cephalitis with intracerebellar abscess formation.
Cerebrospinal  ﬂ   uid (CSF) obtained through lumbar 
puncture was negative for Toxoplasma gondii, Encephali-
tozoon cuniculi, and Enterocytozoon bieneusi by PCR and 
for Trypanosoma gambiense by indirect hemagglutination 
assay. Staining and antigen testing (enzyme immunoas-
say) for Cryptococcus neoformans was negative, as was 
Treponema pallidum antibody testing. No viruses (herpes 
simplex 1 and 2, varicella zoster, enterovirus) could be 
detected by PCR. Cultures were negative for aerobic/
anaerobic bacteria and fungi. ZN staining detected acid-fast 
bacilli that were conﬁ  rmed to be nonresistant M. tubercu-
losis after culture for 38 days. PCR for M. tuberculosis was 
positive. An Acanthamoeba–speciﬁ  c PCR (1) and DNA 
sequencing of the PCR product showed Acanthamoeba 
genotype T2 (corresponding to group III). High immu-
noglobulin (Ig) G (2,000) and IgM (1,000) titers against 
Acanthamoeba spp. could be demonstrated serologically. 
The organism could not be grown in culture (2).
Two skin-biopsy specimens were obtained; they 
showed necrotizing granulomatous inﬂ  ammation affect-
ing the entire dermal thickness and subcutis. Stains and 
culture were negative for Mycobacterium spp., fungi, and 
Acanthamoeba spp. but the specimens tested positive for 
acanthamoebae by PCR. In addition to a standard tuber-
culostatic 5-drug regimen including intravenous strep-
tomycin, empiric anti-amoebic treatment based on data 
retrieved from the few case reports of successful treat-
ment of systemic Acanthamoeba infections (3–5) was ini-
tiated. The regimen included a combination of parenteral 
trimethoprim/sulfamethoxazole (later changed to oral sul-
fadiazine) and parenteral ﬂ  uconazole. CSF samples drawn 
2 and 8 weeks after initiation of therapy tested negative 
for mycobacteria by ZN staining, PCR, and culture but 
remained positive for Acanthamoeba sp. by PCR.
Transbronchial lung biopsy specimens from a second 
bronchoscopy performed 1 month after admission tested 
negative for mycobacteria by ZN staining, PCR, and culture 
but positive for Acanthamoeba sp. by PCR. Acanthamoe-
bae could not be cultivated from bronchial secretions or bi-
opsy sample; immunostaining that used a polyclonal rabbit 
anti–A. castellanii (genotype T4) serum was negative.
Within 12 weeks after initiation of tuberculostatic ther-
apy, complete clinical and radiologic resolution of miliary 
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and the CD4+ lymphocyte count increased to 421 cells/μL. 
Nevertheless, the neurologic status of the patient deterio-
rated, even after liposomal amphotericin B and ﬂ  ucytosine 
had been added to the regimen. Consecutive cranial CT and 
cranial MRI scans demonstrated progression of the lesions, 
with the biggest lesion (1.8 cm in diameter) located in the 
right cerebellopontine angle and cerebellum (Figure 2, pan-
els A and B).
As skin lesions were also gaining size, treatment with 
miltefosine, a phosphocholine analog that has proven suc-
cessful in treating visceral leishmaniasis (6) and is highly 
effective against acanthamoebae in vitro (7,8), was initi-
ated topically as a solution, 60 mg/mL, 1 drop applied 
directly to each skin lesion 2 times a day. After dramatic 
improvements of the skin lesions were observed within 
only 3 weeks (Figure 1, panel C), our patient began pero-
ral miltefosine 100 mg/day (2.5 mg/kg); all other drugs 
except the tuberculostatic 5-drug regimen were stopped.
On MRI scan, performed 8 weeks after admission, 
the brain abscess located in the right cerebellopontine 
angle had reached a size of 4 cm, leading to a rise of in-
tracranial pressure that could not be controlled by intra-
venous administration of mannitol and dexamethasone. 
Nine weeks after admission, an Ommaya Reservoir was 
implanted, and up to 100 mL of CSF was drained daily 
to control intracranial pressure. Amikacin, the only other 
drug that seemed to have some efﬁ  cacy against Acan-
thamoeba spp. in vitro (2), was given intrathecally and 
intravenously (20 mg/2 mL intrathecally + 1,000 mg/d 
intravenously) in place of the streptomycin originally in-
cluded in the 5-drug regimen, under continuous monitor-
ing of peak and trough levels in CSF and blood. A surgi-
cal excision of the abscess was performed 3 weeks later. 
The histologic specimen of this lesion was again positive 
for Acanthamoeba sp. by PCR but negative by immunos-
taining. Neither acanthamoebae nor mycobacteria could 
be grown in culture, despite positive ZN staining of the 
specimen (Table).
Under ongoing therapy with miltefosine, amikacin, 
and 4 more tuberculostatic drugs, the patient improved. 
The remaining cerebral lesions regressed in size. Healing 
of the dermal lesions was achieved within 6 weeks; topical 
miltefosine treatment was stopped after 8 weeks. Intrathe-
cal amikacin and oral miltefosine therapy was halted 6 and 
12 weeks, respectively, after initiation.
A 2-drug tuberculostatic therapy was maintained for 
1 year after the patient had been discharged from hospi-
tal. Two more lumbar punctures were performed 23 and 
29 weeks after the patient was initially evaluated. For the 
ﬁ  rst time neither mycobacteria nor acanthamoebae could 
be detected. CT scan and MR imaging of the brain showed 
no major pathology. Serologic titers, which had gradually 
declined after initiation of miltefosine therapy, reached 
normal levels. The patient was transferred to a specialized 
neurologic institution for rehabilitation. Ataxia and hearing 
impairment did not improve. During the next 24 months, 
the patient was regularly seen in our outpatient clinic. No 
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Figure 1. Ulcer with purulent discharge located on the skull (A) and on the back at ﬁ  rst examination (B) and 17 days after topical treatment 
with miltefosine was initiated (C).
Figure 2. Axial brain magnetic resonance imaging at the level of the 
cerebellum performed 6 weeks after initial consultation. A) Contrast-
enhanced T1 weighted image showing several ring-enhancing 
lesions in the right cerebellar hemisphere and the right cerebellar 
peduncle. B) The corresponding ﬂ  uid attenuation inversion recovery 
image illustrates the extensive perifocal edema exerting a severe 
mass effect through compression and displacement of the fourth 
ventricle with consecutive enlargement of the lateral ventricle.Treatment of Disseminated Acanthamoeba sp. Infection
signs of infection could be found, and Acanthamoeba im-
munoreactivity remained below cutoff.
Disseminated acanthamoeba infection is a rare disease 
characterized by widespread granulomatous inﬁ  ltration 
of the skin and extracerebral organs; it usually occurs in 
immunocompromised patients. Most reported cases have 
progressed to granulomatous amoebic encephalitis (GAE). 
The incidence of GAE is low in spite of the ubiquity of 
these amoebae. Although <200 cases of GAE have been 
described worldwide, it is still of substantial medical rel-
evance because it is usually fatal due to diagnostic difﬁ  cul-
ties (9,10) and lack of effective treatment.
In our patient, co-infection with M. tuberculosis with 
severe immunosuppression may have contributed to his 
susceptibility to acanthamoeba infection but not to the dis-
ease progression and clinical deterioration seen even after 
TB could be controlled. Problems in culturing acanthamoe-
bae from clinical specimens have been reported frequently, 
and isolation of amoebae from CSF is generally uncom-
mon (11). In our case no reactivity to immunoﬂ  uorescence 
was seen, either because the biopsy missed the area of 
active infection or because of the low sensitivity of poly-
clonal antibodies available. Nevertheless, early diagnosis 
of acanthamoeba infection in our patient was achieved by 
molecular methods that proved to be more sensitive than 
microscopy and culture.
GAE and cutaneous acanthamoeba infections have 
been empirically treated with a wide array of antimicro-
bial agents. The outcome has been mostly failure (3,11,12), 
except for a few cases that occurred in immunocompetent 
patients (10,13–15). Few case studies reported successful 
treatment of patients with a solitary brain lesion or initia-
tion of therapy before the infection entered the brain (5,10). 
The ﬁ  rst successful treatment of AIDS-related GAE was 
reported in 2000 (4).
The condition of our patient deteriorated under empiri-
cal treatment with antimicrobial agents previously used to 
treat acanthamoeba infection. When anti-amoebic therapy 
was changed to peroral and topical miltefosine, the skin 
lesions healed and the brain lesions regressed. After the 
remaining brain lesion had been surgically excised, the pa-
tient could be discharged from the hospital. Two years after 
treatment ended, the patient is partly rehabilitated with no 
signs of amoebic or mycobacterial infection.
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